[HTML][HTML] Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy

D Ciardiello, PP Vitiello, C Cardone, G Martini… - Cancer treatment …, 2019 - Elsevier
A better knowledge of the complex interactions between cancer cells and the immune
system has led to novel immunotherapy approaches. Treatment with selective anti-PD1, anti …

[HTML][HTML] Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

…, D Ciardiello, G Martini, T Troiani, C Cardone… - Annals of …, 2020 - Elsevier
Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

[HTML][HTML] Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer

…, G Martini, C Della Corte, C Cardone… - World journal of …, 2016 - ncbi.nlm.nih.gov
The prognosis of patients with metastatic colorectal cancer (mCRC) remain poor despite the
impressive improvement of treatments observed over the last 20 years that led to an …

[HTML][HTML] Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

…, C Mussini, EA Negri, G Botti, C Cardone… - Journal of translational …, 2020 - Springer
Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients …

Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial

…, G Santabarbara, C Pinto, D Santini, C Cardone… - JAMA …, 2021 - jamanetwork.com
Importance Rechallenge therapy with anti–epidermal growth factor receptor (EGFR) drugs
has been suggested in patients with chemo-refractoryRASwild-type (WT) metastatic …

Prolonged QT period in diabetic autonomic neuropathy: a possible role in sudden cardiac death?

…, M Ferri, L Guarini, G Bax, A Piccoli, C Cardone… - Heart, 1988 - heart.bmj.com
Twenty four men with insulin dependent diabetes and different degrees of autonomic
neuropathy were studied to establish the response of the QT interval to various heart rates …

[HTML][HTML] Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective

…, A Passaro, C Criscitiello, C Cremolini, C Cardone… - ESMO open, 2020 - Elsevier
At the end of 2019, a novel severe acute respiratory syndrome (SARS) coronavirus (CoV),
named SARS-CoV-2 or 2019-nCoV, has been identified as the microbial agent causing viral …

[HTML][HTML] Present and future of metastatic colorectal cancer treatment: a review of new candidate targets

G Martini, T Troiani, C Cardone, P Vitiello… - World journal of …, 2017 - ncbi.nlm.nih.gov
In the last two decades, great efforts have been made in the treatment of metastatic
colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs …

[HTML][HTML] RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI …

…, RE Abate, M Lambiase, L Forgione, C Cardone… - Annals of …, 2018 - Elsevier
Background Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal
carcinoma (mCRC) patients. Little information is available on the predictive role of liquid …

[HTML][HTML] Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus …

…, E Martinelli, T Troiani, S Pisconti, C Cardone… - Annals of …, 2016 - Elsevier
Background Cetuximab plus chemotherapy is a first-line treatment option in metastatic
KRAS and NRAS wild-type colorectal cancer (CRC) patients. No data are currently available …